Go to symposium website → www.slas.org/HighContentAnalysis
Back To Schedule
Monday, October 21 • 2:30pm - 3:00pm
Poster Presentation #1- High-Throughput Drug Screening with Advanced Cell-Based Assays

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

High-Throughput drug screening with advanced cell-based assays

Booij T.H., Hirt C., Keller D., Taube D., Prummer M., Riegler E.M., Stirnimann C., Schwank G.

Lab automation has enabled miniaturization and high-throughput screening approaches in drug research, allowing increased numbers of potential drugs to be tested in in vitro assays. Screens have largely been performed using simple 2D cell culture assays to minimize assay variability. However, it is increasingly being recognized that simple 2D cell culture assays may not adequately represent human disease, causing poor translatability from in vitro results to in vivo experiments. As a result, more advanced assays have gained popularity, such as 3D cell culture assays with cultured cell lines, or the use of patient material as PDX- or organoid models. While the use of such assays has, initially, largely been limited to neoplastic disorders such as cancer and cystic diseases, these models are gaining in popularity for other indications, especially where in vitro experimentation has not been general practice.

A limitation of more advanced cell-based assays with PDX- or organoid model systems has been to automate the liquid-handling procedures to enable high-throughput drug screening in these models. The main factors holding back this development include reagent costs, difficulties with liquid handling of viscous reagents, and the increased assay variation that is inherent to the growth of ‘mini-organs’ in normal tissue culture.
We have established a statistically robust organoid screening platform for pancreatic cancer that integrates fully-automated liquid handling, plate transfer and readouts. This screening platform was applied to screen a drug library that can allow for rapid drug repurposing, possibly providing new lead compounds for this, so far, largely incurable disease.


David Keller

Lab Technician, ETH Zurich NEXUS Personalized Health Technologies

Monday October 21, 2019 2:30pm - 3:00pm BST
Sherry Coutu Seminar Suite Foyer